Genentech’s Hardy to become CEO at BioMarin
Plus: BMS CEO Boerner appointed chair, and updates from Storm, Amarin, CTRL, Lakewood, Vesica and RS
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) named Alexander Hardy as CEO effective Dec. 1, when Chairman and CEO Jean-Jacques Bienaimé retires. Hardy will also serve on BioMarin’s board, along with new Chair Richard Meier. Hardy has worked at Roche (SIX:ROG; OTCQX:RHHBY)
and Genentech Inc. since 2005 and has been CEO of Genentech since 2019. Before that, he spent about five years at Novartis AG (SIX:NOVN; NYSE:NVS).
On his first day as CEO, Bristol Myers Squibb Co. (NYSE:BMY) appointed Christopher Boerner as chair of the company’s board of directors, with an effective date of April 1, 2024. Boerner will take over from Chairman Giovanni Caforio, whom Boerner also succeeded as CEO and who is retiring after 23 years with the company. Boerner joined BMS in 2015 and was named EVP and COO in 2018, then CEO-elect on April 26. ...